oxidase

D-Cysteine, the D-isomer of cysteine, is a powerful inhibitor of E. coli growth and is mediated by D-amino acid oxidase to produce H2S, serving as a neuroprotective agent against cerebellar ataxia. Additionally, D-cysteine can inhibit the growth and cariogenicity of a two-species biofilm formed by Streptococcus mutans and Streptococcus hemoglobin.

J-147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

Nitrofen is a selective contact herbicide that acts as an inhibitor of protoporphyrinogen oxidase and retinal dehydrogenase.

Norharmane (β-Carboline) is a natural β-carboline first isolated from plants of the Zygophyllaceae family.

1,4-Naphthoquinone (P-Naphthoquinone) was used as a potential inhibitor of monoamine oxidase and DNA topoisomerase activities[2]. It was also used to inhibit the acetyltransferase activity[1].

1, 5-Isoquinolinediol is an inhibitor of poly(ADP-ribose) synthetase (PARP1; IC50: 0.39 μM). The poly(ADP-ribose) polymerases (PARPs) form a family of enzymes with roles in DNA repair and apoptosis. 1, 5-Isoquinolinediol has been used to study the role of

Bifemelane hydrochloride is a MAO inhibitor

BI-1467335 HCl(BI 1467335) is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO) that helps improve chronic obstructive pulmonary disease in mice[2].

Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.

LOX-IN-3 dihydrochloride, an inhibitor of lysyl oxidase (LOX), inhibits bovine LOX (IC50<10 μM) and human LOXL2 (IC50<1 μM) activities.

GKT136901 (AK120765) is an inhibitor of NOX1/4.It acts as Selective and Direct Scavenger of Peroxynitrite

Xanthine oxidase-IN-10 (XO8 analog) is an inhibitor of xanthine oxidase (XO) used in gout research.

Glycolic acid oxidase inhibitor 1 (compound 2 in table 1) is an inhibitor of glycolate oxidase, which reduces the risk of kidney stone formation. It also inhibits the contraction of guinea pig ileum induced by slow reactive substances (SRS-A) caused by allergic reactions, and has therapeutic potential for the treatment of allergic diseases such as asthma.

Xanthine oxidase-IN-15 (Compound 6c) is a selective inhibitor of Xanthine oxidase (XO) with an IC50 of 0.13 μM. It inhibits XO by forming stable interactions at the enzyme's active site. Xanthine oxidase-IN-15 is primarily utilized in research related to hyperuricemia and gout.

Xanthine oxidase-IN-13 (Compound 10) is a selective inhibitor of xanthine oxidase, with an IC50 of 149.56 μM for bovine xanthine oxidase. It is utilized in the study of inflammatory arthritis.

Cholesteroloxidase-IN-1 (Compound 4) is an inhibitor of cholesterol oxidase (Cholesteroloxidase) with exceptional binding affinity to the enzyme. This compound is potentially useful for research into infection and inflammatory diseases.

Xanthine oxidase-IN-17 is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 298 nM and a Ki of 167 nM. By inhibiting the catalytic activity of XOD, it reduces uric acid production and subsequently decreases the formation of O₂⁻ free radicals. Xanthine oxidase-IN-17 is non-cytotoxic in AML-12 liver cells while effectively inhibiting uric acid formation. It is suitable for research on hyperuricemia and gout.

Xanthine oxidase-IN-18 is a potent orally bioavailable xanthine oxidase (XO) inhibitor with an IC50 of 0.263 μM. It exerts its inhibitory effects by directly and stably binding to the Mo-co active site of xanthine oxidase. Xanthine oxidase-IN-18 also possesses reactive oxygen species (ROS) scavenging capabilities. In a potassium oxonate-induced hyperuricemia rat model, it exhibits antihyperuricemic effects. This compound is applicable in research related to hyperuricemia, breast cancer, and lung cancer.

Xanthine oxidase-IN-21, a Genipin derivative, is an orally effective mixed competitive inhibitor of xanthine oxidase (XOD) with an IC50 of 0.68 μM. It alleviates renal fibrosis by reducing α-SMA expression and modulates the NF-κB pathway to inhibit pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Additionally, Xanthine oxidase-IN-21 suppresses the expression of URAT1 and GLUT9, promoting uric acid excretion and lowering serum uric acid levels. This compound exhibits significant hepatorenal protective effects and can be used in research on hyperuricemia.

Xanthine oxidase-IN-20 is a potent and orally active xanthine oxidase (XO) inhibitor, with an IC50 of 1.7 nM. In mouse and rat models of acute hyperuricemia, it significantly reduces serum uric acid (SUA) levels. Xanthine oxidase-IN-20 exhibits good safety and is applicable in research on hyperuricemia and gout.

Xanthine oxidase-IN-7 (compound 1h) is a potent, orally active xanthine oxidase (XO) inhibitor with an IC50 of 0.36 μM, effectively reducing serum uric acid levels and showing potential for hyperuricemia and gout research [1].

Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor with an IC50 of 0.039 μM, suitable for research in hyperuricemia and gout. Xanthine oxidase-IN-4 demonstrates hypouricemic potency in potassium oxonate-induced hyperuricemia rats. [1].

Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active, and selective monoamine oxidase B (MAO-B) inhibitor (IC50 = 0.02 nM) capable of crossing the blood-brain barrier (BBB). It exhibits antioxidant and anti-neuroinflammatory activities and can be used in the study of Parkinson's disease[1].

Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active, and selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 1.33 nM, capable of crossing the blood-brain barrier (BBB). It exhibits antioxidant and anti-neuroinflammatory activities and is useful in the study of Parkinson's disease [1].